Why is Caplin Point Lab falling/rising?

As of 18-Sep, Caplin Point Laboratories Ltd is experiencing a decline in its stock price, currently at 2,315.30, which reflects a decrease of 9.7 points or 0.42%. Despite this drop, the stock has shown positive performance over the past week and month, with returns of 3.52% and 7.71%, respectively. Today, the stock underperformed its sector by 1.47%, although it is trading above its moving averages across various time frames, indicating some underlying strength. The company has demonstrated high management efficiency with a return on equity of 19.84% and has maintained a low debt-to-equity ratio. Additionally, it has reported positive results for the last 12 consecutive quarters, which includes record net sales and profit after tax figures. However, the stock is considered expensive with a high price-to-book value, and while it has generated a return of 17.83% over the past year, its profits have only increased by 18.3%, leading to a relatively high PEG ratio of 1.7.
In the broader market context, Caplin Point Laboratories has outperformed the benchmark Sensex over the past week and month, with the Sensex returning 1.80% and 2.14%, respectively. However, the year-to-date performance shows a decline of 7.45% for Caplin Point compared to a gain of 6.24% for the Sensex, indicating that while the stock has had strong returns in the past year and over longer periods, it is currently lagging behind the broader market. The increase in institutional investor participation, which has risen by 0.65% in the last quarter, suggests a vote of confidence in the company's fundamentals, but the current price movement reflects concerns over its valuation and potential risks associated with its high price-to-earnings metrics.